Hospital expenditures on antimicrobial drugs, antimicrobial management practices, and the effects of these practices were studied. A survey on institutional budget, size, and staffing; intensive care unit drug costs and use evaluations; and pharmacy expenditures, including antimicrobial costs, for 1993 and 1994 was sent to 122 hospitals. The written survey was followed by telephoned questions regarding each institution's antimicrobial management and expenditures, and any perceived link between the two. Hospitals were grouped by size and type, data were normalized to costs per occupied bed and costs per occupied bed per case mix index, and averages for each size category were calculated for general institutional information and expenses per antimicrobial. Eighty-eight institutions (72%) responded. Although 61% to 74% of the respondents used an antimicrobial formulary to restrict drug choices and control costs, average total antimicrobial expenses increased by more than $300 per occupied bed between 1993 and 1994. Only 7% of the institutions saw decreased costs of $500 or more per occupied bed. The most common reasons for these decreases were restructuring of pricing contracts and implementation of educational programs. The replacement of one formulary alternative with another led to increases in the use of antimicrobials other than the replacement drug and often did not produce savings. The replacement of one formulary antimicrobial with another led more to costshifting than to overall savings.

 

This article has been cited by other articles:

				J. A. Paladino, J. L. Sunderlin, M. E. Singer, M. H. Adelman, and J. J. Schentag Influence of extended-spectrum {beta}-lactams on gram-negative bacterial resistance Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1154 - 1159. [Abstract] [Full Text] [PDF]

				J. A. Paladino, J. L. Sunderlin, M. H. Adelman, M. E. Singer, and J. J. Schentag Observations on vancomycin use in U.S. hospitals Am. J. Health Syst. Pharm., August 1, 2007; 64(15): 1633 - 1641. [Abstract] [Full Text] [PDF]

				G. S. Itokazu, D. N. Schwartz, K. W. Garey, K. A. Rodvold, L. H. Danziger, and R. A. Weinstein Pharmacists' perceptions of the effectiveness of antimicrobial control programs Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2504 - 2508. [Abstract] [Full Text] [PDF]

				D. Raveh, E. Muallem-Zilcha, A. Greenberg, Y. Wiener-Well, Y. Schlesinger, and A.M. Yinnon Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem QJM, June 1, 2006; 99(6): 397 - 406. [Abstract] [Full Text] [PDF]

				J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials Ann. Pharmacother., October 1, 2003; 37(10): 1478 - 1488. [Abstract] [Full Text] [PDF]

				A. Ortqvist Treatment of community-acquired lower respiratory tract infections in adults Eur. Respir. J., July 1, 2002; 20(36_suppl): 40S - 53s. [Abstract] [Full Text] [PDF]